Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

NCT00402467 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00402467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00402467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
November 30, 2004
Enrollment
613 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism